Overall, these data indicate that the FLRT3-UNC5B axis could suppress CAR-T therapy, as well as BiTE therapies designed to promote antitumor T cell immunity, potentially through inhibition of T cell infiltration to the TME, and reduced engagement of T cells with tumor cells. The gene discussed is FLRT3; the disease is neoplasm.